Observation on clinical effect of apatinib mesylate combined with Huoxue Lishui prescript in the treatment of malignant ascites
Objective To explore the clinical effect and safety of apatinib mesylate combined with Huoxue Lishui prescript in the treatment of malignant ascites.Methods A retrospective analysis was performed on 40 patients with malignant ascites.They were divided into an experimental group(20 cases)and a control group(20 cases)according to random numerical table.The control group was given support treatment and apatinib mesylate tablet,and the experimental group was given Huoxue Lishui prescript"Tiaoyingyin"orally on the basis of the control group.Comparison was made on short-term objective efficacy,traditional Chinese medicine syndrome efficacy,traditional Chinese medicine syndrome score,depth of ascites detected by B-ultrasound and quality of life score before and after treatment,and the occurrence of adverse reactions between the two groups.Results Compared with the control group(70.00%),the short-term objective efficacy of the experimental group(95.00%)was higher(P<0.05).Compared with the control group(60.00%),the therapeutic effect of traditional Chinese medicine syndrome in the experimental group(90.00%)was higher(P<0.05).Compared with before treatment,traditional Chinese medicine syndrome score,depth of ascites detected by B-ultrasound and score of quality of life in symptom domain decreased,while the score of quality of life in functional domain and overall health status increased in both groups after treatment(P<0.05).After treatment,the traditional Chinese medicine syndrome score of the experimental group was(11.45±2.61)points,the depth of ascites detected by B-ultrasound was(42.63±11.41)mm,and the score of quality of life in symptom domain was(20.26±15.48)points,which was lower than(13.22±2.77),(51.28±14.66)mm,and(31.48±16.42)points in the control group;the scores of quality of life in functional domain and overall health status in the experimental group were(61.55±9.09)and(36.57±11.28)points,which were higher than(55.33±8.90)and(29.55±10.13)points in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Apatinib mesylate combined with Huoxue Lishui prescript is effective in the treatment of malignant ascites,and is a safe and effective regimen with few adverse reactions and good acceptance by patients.
NETL
NSTL
万方数据
